1. Early Management of NSTE-ACS: From the ED to the Cath Lab

2. Main Limitations of UFH

3. Fondaparinux*

4. Bivalirudin

5. Otamixaban

6. Early Management of NSTE-ACS: From the ED to the Cath Lab

7. Evaluation of Chest Pain

8. ACCF/AHA Recommendations for Initial Management of UA/NSTEMI

9. ESSENCE: TIMI Risk Score and Treatment Effect

10. TIMACS: Early vs Delayed Intervention Stratified by GRACE Score

11. SYNERGY: Postrandomization Crossover From Enoxaparin to Unfractionated Heparin

12. Otamixaban: In Clinical Development for Management of ACS

13. SEPIA-ACS TIMI 42: Otamixaban vs UFH + Eptifibatide in High-Risk NSTEMI ACS

14. TAO: Study Design

18. References

19. References (cont)

20. References (cont)

21. References (cont)